Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 19, 2018
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 21, 2018
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 12, 2018
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
Nov 07, 2018
Amneal Announces Solid Third Quarter 2018 Financial Results
Oct 25, 2018
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
Oct 24, 2018
Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa
Oct 23, 2018
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
Oct 19, 2018
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
Oct 19, 2018
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
Sep 24, 2018
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 21, 2018
Amneal to Report Third Quarter 2018 Results on November 7, 2018
Sep 12, 2018
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
Aug 31, 2018
Amneal to Present at Upcoming Investor Conferences
Aug 31, 2018
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
Aug 20, 2018
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
Aug 09, 2018
Amneal Announces Solid Second Quarter 2018 Financial Results
Jul 23, 2018
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
Jun 29, 2018
Amneal to Report Second Quarter 2018 Results on August 9, 2018
Jun 29, 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
Jun 20, 2018
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary®
Jun 06, 2018
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
May 30, 2018
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
May 18, 2018
Amneal Pharmaceuticals Celebrates Combination by Ringing Opening Bell at New York Stock Exchange
May 17, 2018
Amneal Announces FDA Approval and Launch of Generic Welchol® (Colesevelam HCl) Tablets, 625 mg
May 15, 2018
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
May 14, 2018
Amneal to Present at the UBS Global Healthcare Conference
May 11, 2018
Amneal Announces Actions to Streamline Operations and Capture Cost Synergies
May 07, 2018
Amneal Initiates Phase 3 Study for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa (CD-LD) in Advanced Parkinson's Disease Patients
May 07, 2018
Amneal and Impax Complete Business Combination
May 02, 2018
Amneal Launches Generic for Sabril®: Vigabatrin for Oral Solution, USP
Apr 27, 2018
Amneal And Impax Receive FTC Clearance For Business Combination
Apr 06, 2018
Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)
Mar 27, 2018
Impax Shareholders Approve Proposed Business Combination with Amneal
Mar 14, 2018
Amneal Gains Approval for Erythromycin Tablets, USP
PDF format download (opens in new window)
Mar 12, 2018
Amneal Launches Generic for Gabitril®
PDF format download (opens in new window)
Mar 07, 2018
Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference
Mar 07, 2018
Joint Amneal-Impax Lender Presentation
PDF format download (opens in new window)
Mar 02, 2018
Amneal 4th Quarter & Full Year 2017 Quarterly Financial Report
PDF format download (opens in new window)
Mar 01, 2018
Amneal Launches Generic for Tamiflu® Oral Suspension
PDF format download (opens in new window)
Mar 01, 2018
Impax Reports Fourth Quarter and Full Year 2017 Results
Feb 21, 2018
Amneal Introduces Generic for Namenda XR®
PDF format download (opens in new window)
Feb 20, 2018
Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
Feb 06, 2018
Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
Feb 05, 2018
Amneal Launches AB-Rated Generic for Concerta®
PDF format download (opens in new window)
Feb 01, 2018
Amneal Introduces Isotretinoin Capsules
PDF format download (opens in new window)
Jan 23, 2018
PSEG Long Island Presents Amneal Facility with Energy-Efficiency Rebates
PDF format download (opens in new window)
Jan 18, 2018
Amneal Biosciences Launches Budesonide Capsules
PDF format download (opens in new window)
Jan 16, 2018
Impax to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018
Jan 04, 2018
Amneal Biosciences Introduces Busulfan Injection, Generic for Busulfex®
PDF format download (opens in new window)
Jan 03, 2018
Amneal and Impax to Present at J.P. Morgan Healthcare Conference
PDF format download (opens in new window)
Jan 03, 2018
Amneal Pharmaceuticals and Impax Laboratories to Present at the 36th Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top